Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

12/3/2024

Janusmed kön och genus

Janusmed kön och genus – aripiprazolmonohydrat

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Aripiprazol Testmiljö

Aripiprazol

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Abilify (aripiprazole). Full prescribing information. Food and Drug Administration [www]. [updated 2016-08-01, cited 2020-06-03].

  2. Belmonte C, Ochoa D, Román M, Saiz-Rodríguez M, Wojnicz A, Gómez-Sánchez CI et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018;122(6):596-605.

  3. Abilify (aripiprazole). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-05-07, 2020-06-23]

  4. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry . 2007;68(6):843-853.

  5. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychopharmacol. 2008;28(2):156-65.

  6. De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy. 2013;33(6):603-14.

  7. Stephen Marder, MD and T Scott Stroup, MD, MPH. Pharmacotherapy for schizophrenia: Side effect management. UpToDate [www]. [updated 2019-10-16, cited 2020-06-30].

  8. Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Valdizan EM, Pérez-Iglesias R, Amado-Señaris JA, Garcia-Unzueta MT, Labad J, Correll C, Ayesa-Arriola R. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study. Schizophr Res. 2017;189:134-141.

  9. Veselinović T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011;31(2):214-220.

  10. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32.

  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Abilify (aripiprazole). Full prescribing information. Food and Drug Administration [www]. [updated 2016-08-01, cited 2020-06-03].
  2. Belmonte C, Ochoa D, Román M, Saiz-Rodríguez M, Wojnicz A, Gómez-Sánchez CI et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018;122(6):596-605.
  3. Abilify (aripiprazole). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-05-07, 2020-06-23]
  4. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry . 2007;68(6):843-853.
  5. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychopharmacol. 2008;28(2):156-65.
  6. De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy. 2013;33(6):603-14.
  7. Stephen Marder, MD and T Scott Stroup, MD, MPH. Pharmacotherapy for schizophrenia: Side effect management. UpToDate [www]. [updated 2019-10-16, cited 2020-06-30].
  8. Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Valdizan EM, Pérez-Iglesias R, Amado-Señaris JA, Garcia-Unzueta MT, Labad J, Correll C, Ayesa-Arriola R. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study. Schizophr Res. 2017;189:134-141.
  9. Veselinović T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011;31(2):214-220.
  10. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32.
  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]